Logo

American Heart Association

  25
  0


Final ID:

Interventional Cardiovascular Genomics

  • Natarajan, Pradeep  ( Massachusetts General Hospital , Brookline , Massachusetts , United States )
  • Author Disclosures:
    Pradeep Natarajan: DO have relevant financial relationships ; Researcher:Amgen, Genentech / Roche:Active (exists now) ; Other (please indicate in the box next to the company name):Vertex Pharmaceuticals (spousal employment):Active (exists now) ; Ownership Interest:Bolt, Candela, Mercury, MyOme, Parameter Health, Preciseli, TenSixteen Bio:Active (exists now) ; Consultant:Allelica, CRISPR Therapeutics, Genentech/Roche, HeartFlow, Magnet Biomedicine:Past (completed) ; Consultant:AstraZeneca, Blackstone Life Sciences, Bristol Myers Squibb, Eli Lilly & Co, Esperion Therapeutics, Foresite Capital, Foresite Labs, GV, Merck, Novartis, Novo Nordisk, TenSixteen Bio, Tourmaline Bio:Active (exists now) ; Researcher:Allelica, Novartis:Past (completed)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Genomic and Epidemiology Mid-Career Research Award and Lecture

Monday, 11/10/2025 , 08:00AM - 09:15AM

Abstract Oral Session

More abstracts on this topic:
GLP-1 Receptor Agonists in Non-Diabetic Obese Adults: A Retrospective Cohort Study of Cardiovascular and Arrhythmia Outcomes

Jarrar Yaman, Alkhatib Ahmad, Al Shaikhli Mustafa, Otabor Emmanuel, Eldawud Daoud, Alomari Laith

Genetic Evidence Suggests Combined Inhibition of Lipoprotein(a) and PCSK9 to Lower Atherosclerotic Cardiovascular Disease Risk.

Steinfeldt Jakob, Kaisinger Lena, Buergel Thore, Wikstrom Johannes, Gan Li-ming, Gabrielsen Anders

More abstracts from these authors:
Panel Participant

Natarajan Pradeep

Can understanding CKM risk in South Asian populations help ALL OF US?

Bhattacharya Romit, Natarajan Pradeep

You have to be authorized to contact abstract author. Please, Login
Not Available